迈向1型糖尿病的疾病修饰疗法:聚焦Teplizumab
全球1型糖尿病发病率持续上升,在胰岛素问世百年后,Teplizumab获监管批准用于延迟3期疾病发作,标志着从对症治疗向疾病修饰疗法的转变。本文综述Teplizumab的作用机制,并将其置于新兴疾病修饰疗法的临床实践背景中,以临床医生易于理解的语言进行阐述。
要点
- Teplizumab是人源化单克隆抗体,结合T淋巴细胞CD3分子的ε链。
- Teplizumab可将2期向临床3期1型糖尿病的进展延迟近3年。
- 机制涉及部分激动信号后失活,促进β细胞反应性CD8+ T细胞耗竭并诱导调节性T细胞。
核心结论
- Teplizumab获监管批准延迟3期1型糖尿病发作,临床实践进入疾病修饰可成为新标准治疗的时代。
研究设计与样本
- 本文为综述,回顾Teplizumab的作用机制并置于新兴疾病修饰疗法的临床实践背景中。
主要发现
- Teplizumab输注可将2期向临床3期1型糖尿病的进展延迟近3年。
- Teplizumab通过CD3/TCR部分激动信号及后续失活,促进β细胞反应性CD8+ T淋巴细胞耗竭并诱导调节性T淋巴细胞,恢复自身耐受。
临床怎么用
- 全球自身抗体和血糖异常筛查正在实施,以便在无症状阶段、胰岛素治疗需要之前进行干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The worldwide incidence of type 1 diabetes continues to rise at an alarming rate. One hundred years after the introduction of insulin, the long-entertained hope of moving from symptomatic treatment to disease-modifying therapies is finally taking shape with regulatory approval of teplizumab to delay the onset of stage 3 disease. Here we review teplizumab's mechanism of action, setting it against the background of emerging disease-modifying therapies for clinical practice, in language accessible to practicing clinicians. A clinical diagnosis of type 1 diabetes and insulin dependence results from progressive autoimmune destruction of pancreatic β-cells as part of a complicated dialogue between the immune system and the islet. Infusion with teplizumab, a humanized monoclonal antibody that binds the ε-chain of the T lymphocyte CD3 molecule, delays progression from stage 2 to clinical stage 3 type 1 diabetes by almost 3 years. The mechanism of action of teplizumab involves partial agonistic signaling via CD3/TCR and subsequent deactivation, promoting exhaustion of pancreatic β-cell-reactive CD8+ T lymphocytes and induction of regulatory T lymphocytes, thereby restoring self-tolerance. With regulatory approval of this agent, clinical practice has entered a new era for treating people with type 1 diabetes, in which disease modification can become the new standard of care. Implementation of global screening for autoantibodies and dysglycemia is underway, enabling efforts to intervene during asymptomatic stages of the disease before insulin treatment is required.
引用
- Mathieu C, Sims EK, Chatenoud L, et al. Toward Disease-Modifying Therapies in Type 1 Diabetes: Focus on Teplizumab. Diabetes Care. 2026. PMID: 41196630. doi:10.2337/dci25-0066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。